Login to Your Account



Will Democratic Congress Put Drug Industry in Crosshairs?

By Donna Young


Thursday, November 6, 2008
With the Democrats taking the White House and making big gains in the House and Senate Tuesday, congressional oversight of medical product safety will shift from the FDA to industry, and drug and device makers should be prepared to be in the crosshairs, said John Manthei, global co-chair of the health care and life sciences practice at the Washington law firm Latham & Watkins LLP. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription